Last updated: 11/07/2018 01:21:18
A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients with Alzheimer's Disease
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients with Alzheimer's Disease.
Trial description: A study to investigate the safety and tolerability of both single and multiple intravenous administration of GSK933776 in patients with Alzheimer's Disease.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:
Adverse events. Changes suggesting potential adverse events detected in the physical & neurological examination, brain MRI, cognitive status, laboratory parameters, ECG & vital signs.
Timeframe: 12 weeks for Part A; 34 weeks in Part B
Secondary outcomes:
Plasma pharmacokinetic parameters of GSK933776. Pharmacodynamic effects of GSK 933776. CSF detectable levels of GSK933776. Effects of GSK933776 on plasma and CSF biomarkers. Titre & neutralising activity of anti-GSK933776 antibodies. Exploratory PET scan
Timeframe: 12 weeks for Part A; 34 weeks in Part B
Interventions:
Enrollment:
50
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Andreasen N; Simeoni M; Oestlund H; Lisjo P;Fladby T;Loercher A; Byrne G; Murray F; Scott-Stevens P; Zhang G; Bronge L; Zetterberg H; Mistry P; Nordberg A; Yeo A; Khan S; Hilpert J.First Administration of the Fc-Attenuated Anti-ß Amyloid Antibody GSK933776 to Subjects with Mild Alzheimer’s: a Randomised, Placebo-Controlled Study. PLoS ONE.2015;10(3):e0098153
Medical condition
Alzheimer's Disease
Product
GSK933776
Collaborators
Not applicable
Study date(s)
March 2007 to May 2011
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
55 - 80 years
Accepts healthy volunteers
No
- Inclusion criteria:
- Male or female subject with a clinical diagnosis of probable Alzheimer's disease
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria:
- Male or female subject with a clinical diagnosis of probable Alzheimer's disease
- Subject has mild AD with Mini Mental State Examination (MMSE) score 18-26 inclusive at the screening visit.
- Age between 55 and 80 years.
- Female subjects must be post-menopausal or surgically sterile.
- Male subjects whose partner is of child-bearing potential or have been menopausal for <2 years must use an adequate form of contraception.
- Subject has the ability to comply with procedures for cognitive and other testing & is fluent in the language used for the administration of the cognitive tests.
- Subject lives with (or has substantial periods of contact with) a permanent caregiver who is willing to oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status.
- Subject has provided full written informed consent prior to the performance of any protocol-specified procedure.
- Caregiver has provided a full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure. Exclusion criteria:
- History and/or evidence of any other central nervous system (CNS) disorder that could be interpreted as a cause of dementia.
- Subjects currently living in a nursing home.
- Subjects who are unable to provide informed consent due to cognitive status
- Screening brain MRI with 1 or more of the following conditions: not consistent with AD, evidence of other CNS conditions, shows more than minimal vascular changes, more than 3 microhaemorrhage lesions.
- Focal findings on the neurological exam.
- Any contraindication to lumbar puncture.
- History or evidence of significant psychiatric illness such as schizophrenia or bipolar affective disorder or significant neurological disease other than AD.
- TIA/stroke in the last 3 years, type 1 or type 2 diabetes mellitus, active cardiovascular disease, or other uncontrolled risk factors for stroke.
- Current or recent drug or alcohol abuse or dependence or recent or remote history of the same if that could be a contributing factor to the dementia.
- History or evidence of any significant autoimmune disease or disorder.
- History of seizures (excluding febrile seizures in childhood), current blood clotting or bleeding disorder or conditions that predispose to these (e.g. cancer), current clinically significant systemic illness or significant infection within 30 days that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study.
- History of cerebral amyloid antiopathy and/or hypertensive cerebral haemorrhage or with a known risk of intercerebral haemorrhage/microhaemorrhage.
- Treatment which cholinesterase inhibitors, memantine or selegiline unless the therapy was instituted at least 3 months prior to the administration of GSK933776, at a stable dosage in the 2 months prior and the same regimen will be continued for the duration of the trial and the subject is free from any clinically significant side effects attributable to the drug.
- Subjects who have discontinued cholinesterase inhibitors, memantine, cognitive enhancing agents, or drugs that potentially affect cognition in the 60 days prior to screening.
- Unless maintained on a stable dose regimen for at least 30 days prior to screening, any other medications with the potential to affect cognition.
- Use of drugs with platelet anti-aggregant or anti-coagulant properties (excluding the use of aspirin 325 mg/day or less), anticonvulsants for seizures or narcotic medication.
- History of or current chronic use of systemic steroids or other immunosuppressants.
- Prior participation in clinical investigations involving therapeutic monoclonal antibodies or proteins derived from monoclonal antibodies or any investigations of treatments or use of experimental medications for AD or any other investigational medication or device within 60 days prior to screening or within 5 half-lives of use of such a medication prior to screening, whichever is longer.
- Contraindications for MRI: pacemaker, aneurysm clips, artificial heart valves, other metal foreign body, claustrophobia, etc.
- Smoking more than 20 cigarettes or equivalent per day.
Trial location(s)
Location
GSK Investigational Site
Fremantle, Western Australia, Australia, 6160
Status
Study Complete
Location
GSK Investigational Site
Heidelberg Heights, Victoria, Australia, 3084
Status
Study Complete
Showing 1 - 6 of 7 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2011-30-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 106006 can be found on the GSK Clinical Study Register.
Click hereResearchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website